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G2/M checkpointent kinase complexes (CDK) at key cell cycle transitions is dependent on their
dephosphorylation by CDC25 dual-speciﬁcity phosphatases (CDC25A, B and C in human). The CDC25B
phosphatase plays an essential role in controlling the activity of CDK1-cyclin B complexes at the entry into
mitosis and together with polo-like kinase 1 (PLK1) in regulating the resumption of cell cycle progression
after DNA damage-dependent checkpoint arrest in G2. In this study, we analysed the regulation of CDC25B-
dependent mitosis entry by PLK1. We demonstrate that PLK1 activity is essential for the relocation of CDC25B
from the cytoplasm to the nucleus. By gain and loss of function analyses, we show that PLK1 stimulates
CDC25B-induced mitotic entry in both normal conditions and after DNA-damage induced G2/M arrest. Our
results support a model in which the relocalisation of CDC25B to the nucleus at the G2-M transition by PLK1
regulates its mitotic inducing activity.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe Cell Division Cycle 25 (CDC25) family of proteins is highly
conserved, dual speciﬁcity phosphatases that activate cyclin-depen-
dent kinase (CDK) complexes at key cell cycle transition [1]. The
original discovery of CDC25 in yeast [2] led to the identiﬁcation of
three mammalian Cdc25 isoforms: A, B and C. All three CDC25
phosphatases have been implicated in the control of G1/S, in S-phase,
at the G2/M transition and at mitosis. CDC25B is proposed to have a
speciﬁc function in the control of mitosis entry. When overexpressed
in interphase cells, CDC25B, but not CDC25A or CDC25C, induces
premature mitosis [3–6]. More recently, CDC25B has been shown to
activate the centrosomal pool of CDK1-cyclinB [7–9], inducing its
translocation to the nucleus where activation of CDC25C initiates the
ampliﬁcation loop driving the cell into mitosis [1]. CDC25B activity is
regulated by multiple mechanisms [1]. The N-terminal regulatory
domain is subjected to phosphorylation by inhibiting (CHK1, MK2,
p38, PKB/Akt and pEg3) [10–17] and activating kinases (Aurora-A, CK2
and CDK-cyclin) [18–20]. We have recently shown that Aurora-A and
CHK1 phosphorylate and regulate CDC25B at the centrosome [17–19].
These phosphorylations also modulate binding to 14.3.3 proteins that
lead to cytoplasmic sequestration of CDC25B [21,22]. Intracellular
localisation of CDC25B is also regulated via nuclear localisation (NLS)
and nuclear export sequences (NES) [23–26]. Depending on the
experimental conditions, CDC25B is detected in the nucleus and/or in
the cytoplasm in G2 cells [4, 5, 25] and it is clear that CDC25B shuttlesMCP, 118 Route de Narbonne,
l rights reserved.between cytoplasm and nucleus at mitosis onset as recently
demonstrated by time lapse video-microscopy [27].
Upon DNA damage, CDC25 phosphatases are inhibited through
various mechanisms. CDC25B is central to the control of mitosis entry
after activation of checkpoint signalling pathways. Indeed, increased
CDC25B expression leads to the bypass of genotoxic-induced G2/M
checkpoint arrest [28] and accumulation of CDC25B is required to
allow entry into mitosis when damage has been repaired [29–31].
The Polo-like kinase 1, PLK1, an important target of the DNA
damage checkpoint [32], has also been shown to be essential for
mitotic entry when cells recover from a DNA damage checkpoint-
induced arrest [33]. Human PLK1 belongs to a family of four related
kinases characterized by a serine/threonine kinase domain at the
amino terminus and conserved sequences named polo boxes at the
carboxyl terminus. These regulate cellular function, centrosomal
localisation and substrate interaction [34–40]. PLK1 has been shown
to control mitotic entry [41] at different levels. PLK1 phosphorylates
the NES of CDC25C, leading to its nuclear translocation [42]. PLX1, the
Xenopus ortholog of PLK1, phosphorylates and activates CDC25C and is
required for the CDK1/CylinB autoampliﬁcation loop with CDC25C
[43–45]. Regulation of CDC25C activity by PLK1 in mammals has only
been demonstrated in vitro [46] and the biological consequences in
vivo remain largely unknown. Furthermore, PLK1 phosphorylates
CyclinB but whether it induces CyclinB nuclear localisation or
activation is still a matter of debate [8,47].
Although CDC25B and PLK1 are recognized as playing key roles,
their relationship in the regulation of entry into mitosis and in
checkpoint recovery, albeit suspected, remains unsupported by
conclusive experimental evidence [31,33]. In this study we attempted
to clarify this issue. We report that PLK1 activity relocates CDC25B to
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unperturbed cell cycles and following the DNA damage induced
checkpoint. These results demonstrate the functional regulation of
CDC25B activity by PLK1 in vivo.
2. Materials and methods
2.1. Cell culture
U2OS cells obtained from the American Type Culture Collections
were maintained at 37 °C/5% CO2 in DMEM containing 10% FCS. U2OS
cells expressing HA-CDC25B3 under the tetracycline-regulated pro-
moter were cultured in presence of 2 μg/ml tetracycline. HA-CDC25B3
expression was induced by tetracycline removal. Cells were synchro-
nized using 2.5 mmol/l thymidine for 24 h. Cells were washed twice
with fresh medium and released into thymidine-free mediumwithout
tetracycline, thereby simultaneously releasing the cells from thymi-
dine block and inducing the expression of HA-CDC25B3. Checkpoint
experiments were performed by treating cultures with 40 μM etopo-
side for 1 h, and, after washing, cells were cultured for a further 5 h in
presence of 200 ng/ml nocodazole.
PLK1 pharmacological inhibition was performed by using the
GW843682X inhibitor from GlaxoSmithKline R & D [48].
2.2. Plasmids
The CDC25B3 variant was used in all the experiments reported in
this study. For CDC25B3 over-expression the expression vectors
pEGFP-CDC25B3 or pmOrange-CDC25B3 constructed by cloning
CDC25B3 in a pm-Orange expression vector derived by cloning
mOrange from pRSET-mOrange [49] in place of mCherry in
pm-Cherry-C1 plasmid (Clontech) were used. For pmOrange-
CDC25B3Cter, the catalytic domain of CDC25B3 was ampliﬁed
by PCR (5′-CTCAAGCTTCGGAGCTGATTGGAGATTAC-3′ and 5′-
GGTGGATCCGGCGCAGGCCCC-3′) and cloned into the pm-Orange
plasmid using HindIII and BamHI restriction enzymes. The expression
vector pMP-mcherry-CDC25B3 allows the expression of CDC25B3
under the murine minimal promoter [27]. pcDNA3-PLK1-SDTD-Flag
and pcDNA3-PLK1-7A-Flag were obtained by replacing the EcoRI-
XmaI fragment of pcDNA3-PLK1-Flag with the same fragment from
pcDL-Sra-HA tagged PLK1-SDTD or 7A provided by E. Nishida. The
pRcCMV-myc-PLK1 K82R (PLK1-KD) plasmid was kindly provided by
E. Nigg.
2.3. DNA transfection
For transient transfection, cells were seeded on poly-L-lysine-
coated glass coverslips in 60mmdiameter culture dishes at a density of
500,000 cells/plate and allowed to attach for 24 h before transfection.
Cells were then transfected with 1.5 μg of DNA of the indicated
expression vectors using Lipofectin reagent (Life Technologies) accord-
ing to the manufacturer's instructions. Four hours post-transfection,
serum free medium was replaced by fresh medium for further 4 h, or
medium-containing etoposide for checkpoint experiments.
2.4. Immunoﬂuorescence microscopy
Immunoﬂuorescence studies were performed as previously
described [50]. Anti-γ tubulin (GTU-88) monoclonal antibody was
purchased from Sigma-Aldrich. Anti-phosphorylated histone H3 poly-
clonal antibody and anti-γH2AX (JBW301) monoclonal antibody were
purchased fromUpstate. Anti-mycmonoclonal antibodywas fromSanta
Cruz and anti-Flag polyclonal antibody was purchased from Sigma
Aldrich. DNA was visualised using DAPI staining. Cell countings and
images acquisition were performed by using a DM5000 microscope
(Leica) ﬁtted with a Roper COOLsnap ES CCD camera. Images wereprocessed using the MetaMorph and ImageJ softwares. The nuclear
versus cytoplasmic localisation of GFP-CDC25Bormcherry-CDC25Bwas
analysed as follows: cells with clear nuclear signal were scored as NNC,
cells with pan-cellular signal were scored as N=C and cells with less
signal in the nucleus compare to the cytoplasmwere scored as NbC.
2.5. Flow cytometry
Flow cytometry analyses were performed as previously described
[50]. Cells over-expressing CDC25B3 were detected using an anti-HA
monoclonal antibody (Babco) and phospho-histone H3 positivity was
determined using either a polyclonal antibody from Upstate or the
monoclonal mitotic marker 3.12.I.22 [51]. Secondary antibodies labelled
with Alexa 488 or Alexa 647 were from Invitrogen. DNA was labelled
with propidium iodure (10 μg/ml) in the presence of RNAse (1 mg/ml).
2.6. Western blot analysis
Whole-cell lysates were run on a 4–12% NuPAGE Bis–Tris gel
(Invitrogen), transfered to nitrocellulose membranes and analysed
with different antibodies. CDC25B rabbit polyclonal antibody (C-20)
waspurchased fromSanta-CruzBiotechnology. PLK1mousemonoclonal
antibody was purchased from Zymed laboratories. Horseradish perox-
idase conjugated secondaryantibodieswerepurchased fromCell. Signal.
2.7. RNA interference
U2OS cells expressing HA-CDC25B3 under the tetracycline-regu-
lated promoter were transfected with PLK1 siRNA (ON-TARGETplus
SMARTpool, Dharmacon) using Amaxa transfection system with the
cell line nucleofector kit V, 100 pmol siRNA were used for each
tranfection. Cells were cultured without tetracycline to induce HA-
CDC25B3 expression for 24 h, then treated with 40 μM etoposide for
1 h. After washes, cells were grown in 200 ng/ml nocodazole
supplemented DMEM and ﬁxed at the indicated time points.
2.8. Statistical analyses
All statistical analyses were performed using Student's t tests and
Microsoft Excel or Prism software packages.
3. Results and discussion
3.1. Plk1 promotes nuclear localisation of CDC25B
We ﬁrst investigated the possible relationship between PLK1 and
the intracellular localisation of CDC25B. The localisation of a GFP-
CDC25B fusion protein was analysed in exponentially growing U2OS
cells by ﬂuorescence microscopy and nuclear versus cytoplasmic
accumulation was quantitatively monitored (Supplementary data Fig.
S1A). In control conditions, GFP-CDC25B was mostly nuclear (in about
60% of cells) (Supplementary data Fig. S1B). After treatment with the
thiophene benzimidazole ATP-competitive inhibitor of PLK1
(GW843682X) [48] we observed that the nuclear localisation of GFP-
CDC25B was signiﬁcantly diminished (Supplementary data Fig. S1B)
without any obvious change in the cell-cycle distribution of
transfected cells (data not shown). Moreover, co-expression of a
kinase dead form of PLK1 (PLK1-KD) also signiﬁcantly diminished the
nuclear localisation of CDC25B (Supplementary data Fig. S1B),
suggesting that PLK1 kinase activity regulates CDC25B intracellular
localisation. In gain-of-function experiments, co-transfection with a
vector allowing the expression of wild-type PLK1 (PLK1-WT) did not
signiﬁcantly increase nuclear localisation of CDC25B, which is
achieved by the co-expression of a constitutively active PLK1 (PLK1-
SDTD)mutant [42] (Supplementary data Fig. S1C). Co-transfection of a
mutant form of PLK1 in which NLS was inactivated (PLK1-7A) [52],
Fig. 1. Plk1 promotes nuclear localisation of pMP-CDC25B. U2OS cells were transfected
with pMP-CDC25B or co-transfected with PLK1-Flag WT and left untreated (pMP-
CDC25B+PLK1) or treated with 500 nM of the GW8436825X for 4 h before ﬁxation
(pMP-CDC25B+PLK1+GW843682X), or co-transfected with myc tagged PLK1-KD
(pMP-CDC25B+PLK1-KD). Co-transfected cells were detected by anti-Flag or anti-myc
immunodetection and the localisation of CDC25B was analysed 24 h post-transfection.
Bar diagrams represent the mean±SEM of the percentage of cells, stars mean Pb0.001.
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accumulates in the nucleus irrespective of the nuclear localisation of
PLK1 (Supplementary data Fig. S1C). As GFP-CDC25B localisation
could be affected by the overexpression, to conﬁrm our previous
results we analysed the localisation of mcherry-CDC25B under control
of the mouse minimal natural promoter (pMP-CDC25B) [27] (Fig. 1).
Under these experimental conditions, the co-expression of PLK1-WT
induces a signiﬁcant increase in the nuclear localisation of CDC25B
which is inhibited by a 4 h treatment with the pharmacological
inhibitor of PLK1 GW843682X [48], while PLK1-KD has no effect on
CDC25B intracellular localisation (Fig. 1). Taken together these results
demonstrate that PLK1 activity promotes CDC25B nuclear localisation.
A similar situation has been reported for CDC25C although itsFig. 2. Inhibition of PLK1 decreases the prematuremitotic entry induced by CDC25B overexpr
CDC25B conditionally expressing U2OS cells showing an interphasic cell (i), an end-G2 cell w
(m). (B) HA-CDC25B conditionally expressing U2OS cells were grownwith (Control) or witho
PLK1 inhibitor GW843682X at the time of tetracycline removal. Bar diagram represent the m
and GW843682X treatment. The decrease induced by GW843682X treatment of HA-CDC25B
HA-CDC25B over-expression was similar, whole-cell lysates were used for Western blottingfunctional signiﬁcance is unknown. We therefore decided to address
the functional regulation of CDC25B by PLK1.
3.2. Plk1 increases the ability of CDC25B to induce mitosis
We tested the effect of PLK1 inhibition on the ability of CDC25B to
induce premature mitosis entry when over-expressed in S- and G2-
phase [4–6,23,25]. U2OS cells conditionally expressing a HA-epitope
tagged CDC25B [20] were synchronized by thymidine block and
released. At the time of thymidine release, the expression of CDC25B
was induced by tetracycline removal (HA-CDC25B in Fig. 2B) or not
induced (Control in Fig. 2B) and cells were harvested from 4 h to 10 h
post-release. Treatment of cells with GW843682X at the time of
thymidine release induced a clear accumulation of mitotic cells from
8 h in cells overexpressing CDC25B or not, showing that, at the
concentration used, the GW8436825X the inhibitor was able to
efﬁciently suppress PLK1 activity (Supplementary data Fig. S2) [53]. As
this direct consequence of pharmacological inhibition of PLK1 on cell
cycle progression was quite rapidly detectable, we analysed the
consequences of GW843682X treatment on CDC25B-induced pre-
mature mitotic entry as early as 4 h post-release. At this early stage of
the experimental setup, very low percentages of mitotic cells are
detectable (Supplementary data Fig. S2). As shown in Fig. 2A,
immunoﬂuorescence analysis allows the detection of P-H3 labelling
as multiple foci of lower intensity in the nucleus of interphase cells (f
cells in Fig. 2A). This speciﬁc labelling does not correspond to mitotic
cells and it has previously been described in late G2 phase cells that
are about to enter mitosis [54]. So to analyse the consequence of PLK1
inhibition on CDC25B biological activity, we scored these late G2 cells.
At 4 h post-release, almost no positive P-H3 cells were found in
control cells whereas 35% (±5.4 SEM) of cells overexpressing HA-
CDC25B displayed P-H3 positive foci (Fig. 2B). This percentage
dropped signiﬁcantly (to 20%±3.4 SEM) when PLK1 was inhibited by
GW843682X at the time of release, indicating that inhibition of PLK1
decreases the premature progression of cells through G2 phase
toward mitotic entry induced by CDC25B overexpression. This resultession. (A) Immunodetection of phosphorylated histone H3 (P-H3) and γ-tubulin on HA-
ith uncondensed DNA and P-H3 positive foci (f) and a mitotic cell with condensed DNA
ut tetracycline to induce HA-CDC25B expression and treated or not with 250 nM of the
ean±SEM of the percentage of cells with P-H3 foci 4 h after HA-CDC25B overexpression
over-expressing cells was signiﬁcant (Pb0.01, Student's t test). To control that the level of
with C-20 antibody recognizing CDC25B and anti-actin as a load control.
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starter of mitosis.
To further conﬁrm the ability of PLK1 to enhance CDC25B mitotic
inducing activity, gain-of-function experiments were performed.
Exponentially growing human U2OS cells were transiently trans-
fected with plasmids expressing GFP-tagged CDC25B (GFP-CDC25B)
or Flag-tagged PLK1, or co-transfected with the two plasmids. Empty
vector was transfected as a control. The transfected cells were scored
for chromatin condensation by DAPI staining. After 8 h of GFP-
CDC25B overexpression, 28.2% (±4.2 SEM) of cells had condensed
chromatin. This percentage quite doubled (52.3%±4 SEM) when
PLK1 was co-expressed with CDC25B (Fig. 3A). Similar results were
obtained with a mOrange-tagged form of CDC25B although its basal
activity was higher (Fig. 3B). On the contrary, co-expression of a
kinase dead mutant of PLK1 did not signiﬁcantly increase the ability
of CDC25B to induce mitosis (Fig. 3B). As the over-expression of PLK1Fig. 3. Over-expression of PLK1 increases CDC25B ability to induce mitosis. (A) U2OS cells w
Flag (PLK1), pEGFP-CDC25BNLS− (GFP-CDC25BNLS−), pEGFP-CDC25BNLS− and pcDNA3-PLK1-Fla
CDC25B (Or-CDC25B), pmOrange-CDC25B and pcDNA3-PLK1-Flag, pmOrange-CDC25BC
pmOrange-CDC25B and pRcCMV-myc-PLK1 K82R (PLK1-KD), pRcCMV-myc-PLK1 K82R or
or anti-myc antibodies and nuclei stained using DAPI. Bar diagrams represents the mean±S
observed after co-transfection of CDC25B together with PLK1 compared to CDC25B transfect
Western blotting with an anti-PLK1 antibody and an anti-actin antibody as a load control.alone did not have any effect compared to the control, this
observation suggests that PLK1 positively regulates the biological
activity of CDC25B. As mentioned above, the activity of CDC25
phosphatases is regulated by post-translational modiﬁcations of
their amino-terminal regulatory domain. To conﬁrm that the
increase of the percentage of cells with condensed chromatin
observed after co-expression of PLK1 was due to the regulation of
CDC25B activity, we used a construct encoding only the catalytic
domain of CDC25B (Cter) (Fig. 3B). As shown in Fig. 3B, the ability of
this CDC25B form lacking its N-terminal regulatory domain to induce
mitosis was not increased by the co-expression of PLK1, suggesting
that the results observed in Fig. 3A are indeed the consequence of
the regulation of CDC25B biological activity by PLK1. Since PLK1
induces the nuclear localisation of CDC25B, we asked whether PLK1
could still increase the mitosis-inducing activity of a CDC25B mutant
with an inactive NLS (CDC25BNLS−, [24]). In this experiment, theere transfected with pEGFP-CDC25B (GFP-CDC25B), pEGFP-CDC25B and pcDNA3-PLK1-
g, pcDNA3-PLK1-Flag or empty vector. (B) U2OS cells were transfected with pmOrange-
ter (Or-Cter), pmOrange-CDC25BCter and pcDNA3-PLK1-Flag, pcDNA3-PLK1-Flag,
empty vector. Transfected cells were detected by immunoﬂuorescence using anti-Flag
EM of the percentage of cells with condensed DNA 8 h after transfection. The increase
ionwas signiﬁcant (Pb0.01, Student's t test). In parallel, whole-cell lysates were used for
Fig. 4. The G2/M checkpoint bypass induced by CDC25B overexpression was decreased by PLK1 knockdown. (A) HA-CDC25B conditionally expressing U2OS cells were transfected
with PLK1 or scramble (Scr) siRNA and grown in DMEM with (control) or without tetracycline to induce HA-CDC25B expression (HA-CDC25B). After 24 h, G2/M checkpoint is
activated by a 1 h etoposide treatment and cells were then released (time point 0 h) in the presence of nocodazole. Histograms and dot plots represent the DNA content and the
mitotic marker 3.12.I.22 positivity at 22 h post-release as determined by ﬂow cytometry. On dot plots, the horizontal line corresponds to the threshold of 3.12.I.22 positivity and
mitotic cells are the cells identiﬁed in the upper right part (positives for 3.12.I.22 and with a 4n DNA content). The corresponding percentages are indicated. (B) Knockdown of PLK1
following siRNA transfection was controlled by Western blotting 22 h post-release. (C) Bar diagram represents the mean±SEM of the percentage of mitotic cells determined by ﬂow
cytometry as described in A at 9 h and 22 h post-release.
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were not signiﬁcantly different, in agreement with others [25].
Whereas the co-expression of PLK1 induced a roughly two-fold
increase of the mitosis-inducing activity of wild type CDC25B, it led
only to a 50% increase of the activity of the NLS mutant (Fig. 3A). In
all of these experiments, the level of PLK1 overexpression was kept
the same. Altogether, these results demonstrate that PLK1 positively
regulates CDC25B-dependent mitosis entry and that this effect at
least partly requires the capacity of CDC25B to shuttle from the
cytoplasm to the nucleus.
The fact that CDC25BNLS− had a mitosis inducing activity compar-
able towild type CDC25B is consistentwith its centrosomal activity as a
starter of mitosis [1]. Our work demonstrates that PLK1 is responsible
for an enhancement of the mitotic inducer activity of CDC25B by
inducing its localisation to the nucleus, suggesting that besides itscentrosomal function, CDC25B also plays a mitosis inducing role in the
nucleus. This is supported by published data showing that mutation of
the 14.3.3 binding site (S323) of CDC25B increases its nuclear
localisation of CDC25B concomitantly with its ability to induce mitosis
[22,24,25]. Nevertheless, aswehave shown that PLK1 can stillmodestly
increase CDC25BNLS−mitotic-inducing activity, one cannot exclude that
PLK1 also regulates some cytoplasmic aspect of the function of CDC25B.
3.3. Plk1 regulates the G2/M checkpoint bypass dependent on CDC25B
overexpression
Overexpression of the phosphatase CDC25B overcomes a DNA-
damage induced G2/M checkpoint arrest. Moreover, it has been shown
by knockdown experiments that PLK1 is required for recovery from a
DNA damage-induced G2/M arrest. We therefore examined if PLK1
467V. Lobjois et al. / Biochimica et Biophysica Acta 1793 (2009) 462–468could also regulate the biological activity of CDC25B after checkpoint
activation. To this end, U2OS cells conditionally expressing CDC25B
were treated or not with siRNA against PLK1. DNA damage was
induced by a 1 h treatment with etoposide. Cells were subsequently
grown in the presence of nocodazole to trap in mitosis (as detected by
ﬂow cytometry) those that had escaped the G2/M block (Fig. 4A)
[28,55]. As shown in Fig. 4C, the percentage of mitotic cells 22 h after
etoposide treatment was signiﬁcantly lower in the PLK1 siRNA
transfected cells compared to mock-transfected cells. This result
indicates that CDC25B-dependent G2/M checkpoint bypass is inhib-
ited upon PLK1 knockdown.
To conﬁrm these results, U2OS cells were transfected with
plasmids encoding either CDC25B alone, CDC25B plus PLK1, PLK1
alone or empty vector and then treated for 1 h with etoposide and
allowed to grow in the presence of nocodazole. In these experimentalFig. 5. PLK1 over-expression increases the G2/M checkpoint bypass dependent on
CDC25B overexpression. (A) U2OS cells were transfected with pEGFP-CDC25B plasmid.
After 4 h, cells were treated with etoposide for 1 h and then grown for further 5 h in
presence of nocodazole. In these conditions, all the mitotic cells have damaged DNA as
detected by immunoﬂuorescence using an anti-γH2AX antibody. (B) U2OS cells were
transfected with either pEGFP-CDC25B (GFP-CDC25B), pEGFP-CDC25B and pcDNA3-
PLK1-Flag (PLK1), pEGFP-CDC25B-phosphatase dead (GFP-CDC25-PD), pEGFP-CDC25B-
PD and pcDNA3-PLK1-Flag, pcDNA3-PLK1-Flag or empty vector; then treated as
previously described. Bar diagram represents the mean±SEM of the percentage of
mitotic catastrophe. The difference induced by the over-expression of PLK1 together
with CDC25B compared to overexpression of CDC25B was signiﬁcant (Pb0.005,
Student's t test). Whole-cell lysates were used for western blotting with an anti-PLK1
and an anti-CDC25B antibodies. Actin was used as a load control.conditions, all of the cells displaying condensed chromatin 10 h after
transfection were found to be positive for γ-Histone2AX indicating
that they had bypassed the etoposide induced-G2/M checkpoint and
entered into mitosis without having repaired their DNA (Fig. 5A). As
presented in Fig. 5B, 38% (±1.9 SEM) of cells overexpressing CDC25B
displayed condensed chromatin whilst co-expression of PLK1
increased this to 55.5% (±3.5 SEM). Overexpression of PLK1 alone
had no effect. Moreover, the expression of a phosphatase dead mutant
of CDC25B [50] together with PLK1 did not induce G2/M checkpoint
bypass (Fig. 5B). In interphase cells, co-expression of PLK1 increased
the nuclear localisation of CDC25B as observed in unperturbed cells
(data not shown).
Together, these data support a model in which PLK1 positively
regulates the ability of CDC25B to overcome DNA-damage induced
G2-M arrest. It has been previously demonstrated by siRNA treatment
that PLK1 is required for cells to enter mitosis after DNA-damage
induced G2-M arrest and that overexpression of CDC25B rescues this
inhibition [33]. From these results we suspected a relationship
between PLK1 and CDC25B in the control of mitosis entry after G2/
M arrest but independent effects of CDC25B and PLK1 could not be
excluded. Our results reported here functionally demonstrate the
regulation of CDC25B activity by PLK1.
Mitotic entry of cells with damaged DNA depends on PLK1 and
CHK1 inhibition [56]. CHK1 inhibits CDC25B activity in response to
DNA damage-induced G2/M checkpoint activation and activates the
CDK-inhibitory kinases WEE1 and MYT1. On the contrary, PLK1
controls checkpoint hurdle through WEE1 degradation [1]. Here, we
functionally demonstrate that PLK1 regulates the ability of CDC25B to
push cells with unrepaired DNA into mitosis. Indeed, CDC25B appears
to couple the CHK1- and, as suggested by our results, PLK1-dependent
controls of the G2/M checkpoint. CHK1 and PLK1 could control the G2/
M checkpoint by acting on the balance between WEE1 and CDC25B
activities to control CDK-Cyclin complexes.
We propose a model in which PLK1 positively regulates the ability
of CDC25B to inducemitosis partly by inducing its nuclear localisation.
A better understanding of the molecular mechanisms involved will
require the identiﬁcation of PLK1 phosphorylation sites on CDC25B
and the functional consequences of their mutation. These analyses are
currently underway. CDC25B, as well as PLK1, have been shown to be
over-expressed in numerous tumours [1,57,58],making thempotential
pharmacological targets for cancer therapy. Pharmacological inhibitors
of CDC25 phosphatases and PLK1 are currently being developed
[1,58,59] and, on the basis of our observations, the combination of both
type of compounds might have considerable therapeutic potential.Acknowledgements
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